Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations

Gillian R. Langley; Ian M. Adcock; François Busquet; Kevin M. Crofton; Elena Csernok; Christoph Giese; Tuula Heinonen; Kathrin Herrmann; Martin Hofmann-Apitius; Brigitte Landesmann; Lindsay J. Marshall; Emily Mcivor; Alysson R. Muotri; Fozia Noor; Katrin Schutte; Troy Seidle; Anja van de Stolpe; Hilde van Esch; Catherine Willett; Grzegorz Woszczek

doi:10.1016/j.drudis.2016.10.011

Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations

Gillian R. Langley^*
, Ian M. Adcock
, François Busquet
, Kevin M. Crofton
, Elena Csernok
, Christoph Giese
, Tuula Heinonen
, Kathrin Herrmann
, Martin Hofmann-Apitius
, Brigitte Landesmann
, Lindsay J. Marshall
, Emily Mcivor
, Alysson R. Muotri
, Fozia Noor
, Katrin Schutte
, Troy Seidle
, Anja van de Stolpe
, Hilde van Esch
, Catherine Willett
, Grzegorz Woszczek

^*Corresponding author for this work

Humane Society International, London
Imperial College London
Center for Alternatives to Animal Testing (CAAT) Europe, Brussels
US Environmental Protection Agency
Eberhard Karls Universität Tübingen
Esslingen District Clinics GmbH
ProBioGen AG
Tampereen Yliopisto
Free University Berlin
Fraunhofer Institute for Algorithms and Scientific Computing (SCAI)
European Commission Joint Research Centre, Ispra
Rady Children's Hospital
Universität des Saarlandes
European Commission
Humane Society International, Toronto
Philips
University Hospitals Leuven
Humane Society of the United States
King's College London
Guy's Hospital

Research output: Contribution to journal › Article › peer-review

74 Citations (Scopus)

72 Downloads (Pure)

Abstract

Decades of costly failures in translating drug candidates from preclinical disease models to human therapeutic use warrant reconsideration of the priority placed on animal models in biomedical research. Following an international workshop attended by experts from academia, government institutions, research funding bodies, and the corporate and nongovernmental organisation (NGO) sectors, in this consensus report, we analyse, as case studies, five disease areas with major unmet needs for new treatments. In view of the scientifically driven transition towards a human pathway-based paradigm in toxicology, a similar paradigm shift appears to be justified in biomedical research. There is a pressing need for an approach that strategically implements advanced, human biology-based models and tools to understand disease pathways at multiple biological scales. We present recommendations to help achieve this.

Original language	English
Pages (from-to)	327-339
Number of pages	13
Journal	Drug Discovery Today
Volume	22
Issue number	2
Early online date	29 Oct 2016
DOIs	https://doi.org/10.1016/j.drudis.2016.10.011
Publication status	Published - Feb 2017

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

biomedical research
research funding
adverse outcome pathways
21st-century roadmap
human-specific models
human disease pathways

Access to Document

10.1016/j.drudis.2016.10.011

Roadmap for biomedical research and drug discovery
© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
Accepted author manuscript, 744 KBLicence: CC BY-NC-ND 3.0

Cite this

Langley, G. R., Adcock, I. M., Busquet, F., Crofton, K. M., Csernok, E., Giese, C., Heinonen, T., Herrmann, K., Hofmann-Apitius, M., Landesmann, B., Marshall, L. J., Mcivor, E., Muotri, A. R., Noor, F., Schutte, K., Seidle, T., van de Stolpe, A., van Esch, H., Willett, C., & Woszczek, G. (2017). Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations. Drug Discovery Today, 22(2), 327-339. https://doi.org/10.1016/j.drudis.2016.10.011

@article{32b91a6bf28e4613ac809d908933b88b,

title = "Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations",

abstract = "Decades of costly failures in translating drug candidates from preclinical disease models to human therapeutic use warrant reconsideration of the priority placed on animal models in biomedical research. Following an international workshop attended by experts from academia, government institutions, research funding bodies, and the corporate and nongovernmental organisation (NGO) sectors, in this consensus report, we analyse, as case studies, five disease areas with major unmet needs for new treatments. In view of the scientifically driven transition towards a human pathway-based paradigm in toxicology, a similar paradigm shift appears to be justified in biomedical research. There is a pressing need for an approach that strategically implements advanced, human biology-based models and tools to understand disease pathways at multiple biological scales. We present recommendations to help achieve this.",

keywords = "biomedical research, research funding, adverse outcome pathways, 21st-century roadmap, human-specific models, human disease pathways",

author = "Langley, \{Gillian R.\} and Adcock, \{Ian M.\} and Fran{\c c}ois Busquet and Crofton, \{Kevin M.\} and Elena Csernok and Christoph Giese and Tuula Heinonen and Kathrin Herrmann and Martin Hofmann-Apitius and Brigitte Landesmann and Marshall, \{Lindsay J.\} and Emily Mcivor and Muotri, \{Alysson R.\} and Fozia Noor and Katrin Schutte and Troy Seidle and \{van de Stolpe\}, Anja and \{van Esch\}, Hilde and Catherine Willett and Grzegorz Woszczek",

note = "{\textcopyright} 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ ",

year = "2017",

month = feb,

doi = "10.1016/j.drudis.2016.10.011",

language = "English",

volume = "22",

pages = "327--339",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier",

number = "2",

}

Langley, GR, Adcock, IM, Busquet, F, Crofton, KM, Csernok, E, Giese, C, Heinonen, T, Herrmann, K, Hofmann-Apitius, M, Landesmann, B, Marshall, LJ, Mcivor, E, Muotri, AR, Noor, F, Schutte, K, Seidle, T, van de Stolpe, A, van Esch, H, Willett, C & Woszczek, G 2017, 'Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations', Drug Discovery Today, vol. 22, no. 2, pp. 327-339. https://doi.org/10.1016/j.drudis.2016.10.011

TY - JOUR

T1 - Towards a 21st-century roadmap for biomedical research and drug discovery

T2 - consensus report and recommendations

AU - Langley, Gillian R.

AU - Adcock, Ian M.

AU - Busquet, François

AU - Crofton, Kevin M.

AU - Csernok, Elena

AU - Giese, Christoph

AU - Heinonen, Tuula

AU - Herrmann, Kathrin

AU - Hofmann-Apitius, Martin

AU - Landesmann, Brigitte

AU - Marshall, Lindsay J.

AU - Mcivor, Emily

AU - Muotri, Alysson R.

AU - Noor, Fozia

AU - Schutte, Katrin

AU - Seidle, Troy

AU - van de Stolpe, Anja

AU - van Esch, Hilde

AU - Willett, Catherine

AU - Woszczek, Grzegorz

PY - 2017/2

Y1 - 2017/2

N2 - Decades of costly failures in translating drug candidates from preclinical disease models to human therapeutic use warrant reconsideration of the priority placed on animal models in biomedical research. Following an international workshop attended by experts from academia, government institutions, research funding bodies, and the corporate and nongovernmental organisation (NGO) sectors, in this consensus report, we analyse, as case studies, five disease areas with major unmet needs for new treatments. In view of the scientifically driven transition towards a human pathway-based paradigm in toxicology, a similar paradigm shift appears to be justified in biomedical research. There is a pressing need for an approach that strategically implements advanced, human biology-based models and tools to understand disease pathways at multiple biological scales. We present recommendations to help achieve this.

AB - Decades of costly failures in translating drug candidates from preclinical disease models to human therapeutic use warrant reconsideration of the priority placed on animal models in biomedical research. Following an international workshop attended by experts from academia, government institutions, research funding bodies, and the corporate and nongovernmental organisation (NGO) sectors, in this consensus report, we analyse, as case studies, five disease areas with major unmet needs for new treatments. In view of the scientifically driven transition towards a human pathway-based paradigm in toxicology, a similar paradigm shift appears to be justified in biomedical research. There is a pressing need for an approach that strategically implements advanced, human biology-based models and tools to understand disease pathways at multiple biological scales. We present recommendations to help achieve this.

KW - biomedical research

KW - research funding

KW - adverse outcome pathways

KW - 21st-century roadmap

KW - human-specific models

KW - human disease pathways

UR - https://www.scopus.com/pages/publications/85006176599

U2 - 10.1016/j.drudis.2016.10.011

DO - 10.1016/j.drudis.2016.10.011

M3 - Article

SN - 1359-6446

VL - 22

SP - 327

EP - 339

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 2

ER -

Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this